Press Releases July 20, 2026 04:05 PM

TELA Bio to Announce Second Quarter 2026 Financial Results

TELA Bio to Report Q2 2026 Financial Results and Host Earnings Call on August 10, 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
TELA

TELA Bio, a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, announced it will release its second quarter 2026 financial results on August 10, 2026. Management will hold a conference call and webcast to discuss the results and provide a corporate update.

TELA Bio to Announce Second Quarter 2026 Financial Results
TELA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Announcement of Q2 2026 financial results release date: August 10, 2026.
  • Management to hold a conference call and webcast for investors to discuss financial results and corporate updates.
  • TELABio focuses on innovative, economical soft-tissue reconstruction technologies that enhance patient anatomy preservation and restoration.

MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2026 financial results on Monday, August 10, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Second Quarter Earnings Conference Call and Webcast Details
Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the Events & Presentations page of the investor section of TELA's website.

About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact
Louisa Smith
[email protected]


Risks

  • Future financial results and business performance may materially differ due to risks and uncertainties outlined in the company's SEC filings.
  • Dependence on successful commercialization of medical technology products in a competitive healthcare market.
  • Regulatory, market acceptance, and operational risks typical for medical technology companies impact business outcomes.

More from Press Releases

New Fluke TLPV2 Solar Test Lead Set Eliminates Risky Live-Box Voltage Measurements in Operating PV Systems Jul 21, 2026 CoinShares Unveils UCITS Platform, Expanding Access to Europe's €26.3 Trillion Regulated Fund Ecosystem Jul 21, 2026 Enigmatig Limited Invests in KUNGFULAND, First-Scripted Feature-Length Action-Comedy Singapore and Canada Treaty Co-Production Using Virtual Production Jul 21, 2026 Statement of no intention to make an offer for Brera Holdings plc (the “Company”) Jul 21, 2026 Zoom appoints Carlos Quaderi as Head of APAC to drive next phase of AI-powered growth Jul 20, 2026